NCT03312842View on ClinicalTrials.gov

A Phase Ia/Ib Study of CS1001 in Subjects With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

259

Participants

Timeline

Start Date

October 19, 2017

Primary Completion Date

August 16, 2021

Study Completion Date

February 16, 2022

Conditions
Advanced Cancer
Interventions
DRUG

CS1001

"In the dose escalation part, the dose levels will be escalated following a modified 3+3 dose escalation scheme.~In the dose expansion part, patients will be assigned to different groups based on their tumor type."

Trial Locations (2)

100142

Beijing Cancer Hospital, Beijing

Unknown

Fudan University Shanghai Cancer Center, Shanghai

Sponsors
All Listed Sponsors
lead

CStone Pharmaceuticals

INDUSTRY

NCT03312842 - A Phase Ia/Ib Study of CS1001 in Subjects With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter